Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 20/20 | 1.00 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263382 | 0.89 | SUCNR1 (0.82) | SUCNR1OXGR1 | |
| SCHEMBL26264959 | 0.89 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26264914 | 0.86 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26264557 | 0.85 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26266899 | 0.84 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26264926 | 0.84 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26264890 | 0.83 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26263380 | 0.83 | SUCNR1 (0.81) | SUCNR1OXGR1 | |
| SCHEMBL26266993 | 0.82 | SUCNR1 (1.00) | SUCNR1OXGR1 | |
| SCHEMBL26267011 | 0.82 | SUCNR1 (1.00) | SUCNR1OXGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165108-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-23 | — | — | US | claimed |
| EP-4321159-A1 | NOVEL USE OF GPR91 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-02-14 | — | — | EP | claimed |
| US-20240165108-A1 | NOVEL USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| EP-4321159-A1 | NOVEL USE OF GPR91 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023183776-A2 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165108-A1 | NOVEL USE | GPR65, GPR88, GPR27 | SUCNR1 26/4885OXGR1 155/4885 |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885OXGR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.